JP2024540282A5 - - Google Patents
Info
- Publication number
- JP2024540282A5 JP2024540282A5 JP2024526529A JP2024526529A JP2024540282A5 JP 2024540282 A5 JP2024540282 A5 JP 2024540282A5 JP 2024526529 A JP2024526529 A JP 2024526529A JP 2024526529 A JP2024526529 A JP 2024526529A JP 2024540282 A5 JP2024540282 A5 JP 2024540282A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- disorder
- composition according
- compound
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163276117P | 2021-11-05 | 2021-11-05 | |
| US63/276,117 | 2021-11-05 | ||
| PCT/EP2022/056991 WO2022195011A1 (en) | 2021-03-18 | 2022-03-17 | Psilocybin analogs, salts, compositions, and methods of use |
| EPPCT/EP2022/056991 | 2022-03-17 | ||
| PCT/EP2022/076073 WO2023078604A1 (en) | 2021-11-05 | 2022-09-20 | Formulations of psilocybin analogs and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024540282A JP2024540282A (ja) | 2024-10-31 |
| JP2024540282A5 true JP2024540282A5 (https=) | 2025-09-25 |
Family
ID=83558221
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024526529A Pending JP2024540282A (ja) | 2021-11-05 | 2022-09-20 | シロシビン類似体の製剤および使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250213527A1 (https=) |
| EP (1) | EP4426675A1 (https=) |
| JP (1) | JP2024540282A (https=) |
| KR (1) | KR20240095294A (https=) |
| CN (1) | CN117177959A (https=) |
| AU (1) | AU2022381220B2 (https=) |
| CA (1) | CA3236624A1 (https=) |
| IL (1) | IL312175A (https=) |
| WO (1) | WO2023078604A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021226416A1 (en) | 2020-05-08 | 2021-11-11 | Psilera Inc. | Novel compositions of matter and pharmaceutical compositions |
| CA3218110A1 (en) | 2021-05-25 | 2022-12-01 | Majed Fawaz | New n,n-dimethyltryptamine salts and crystalline salt forms |
| KR20240058859A (ko) | 2021-08-12 | 2024-05-03 | 쿨레온 엘엘씨 | 환각성 및 비환각성 세로토닌 수용체 작용제 및 이의 제조 및 사용 방법 |
| WO2023129956A2 (en) | 2021-12-30 | 2023-07-06 | ATAI Life Sciences AG | Dimethyltryptamine analogues as nitric oxide delivery drugs |
| IL315086A (en) * | 2022-06-09 | 2024-10-01 | Diamond Therapeutics Inc | Amorphous (A-polymorphic) psilocybin |
| US12049447B2 (en) | 2022-06-30 | 2024-07-30 | Zylorion Health Inc. | Crystalline forms of compositions comprising psilocin and psilocybin |
| CA3267523A1 (en) * | 2022-09-12 | 2024-03-21 | Tryp Therapeutics, Inc | CRYSTALLINE FORMS OF PSILOCIN |
| AU2024229430A1 (en) | 2023-02-27 | 2025-07-24 | Cybin Irl Limited | Methods of treating depressive disorders with a psilocybin analog |
| WO2025019800A1 (en) * | 2023-07-19 | 2025-01-23 | Atai Therapeutics, Inc. | Novel prodrugs and conjugates of dimethyltryptamine and methods of using the same |
| WO2025101885A1 (en) | 2023-11-09 | 2025-05-15 | Zylorion Health Inc. | Uses of a co-crystal of psilocybin and psilocin |
| WO2025212687A1 (en) * | 2024-04-01 | 2025-10-09 | Tsi Group Co., Ltd. | Compositions and methods of preparation of a clear, effervescent delivery form for nutritional ingredients |
| US20260021070A1 (en) * | 2024-07-19 | 2026-01-22 | Compass Pathfinder Limited | Subcutaneous formulations comprising psilocybin derivatives |
| CN119610304A (zh) * | 2024-12-10 | 2025-03-14 | 澳创新耐火材料(中山)有限公司 | 一种低值植物纤维材料重组防火门芯及其制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5612059A (en) | 1988-08-30 | 1997-03-18 | Pfizer Inc. | Use of asymmetric membranes in delivery devices |
| US5798119A (en) | 1995-06-13 | 1998-08-25 | S. C. Johnson & Son, Inc. | Osmotic-delivery devices having vapor-permeable coatings |
| KR20220137081A (ko) * | 2020-02-04 | 2022-10-11 | 마인드셋 파마 인크. | Cns 장애의 치료를 위한 세로토닌성 사이키델릭 작용제로서의 실로신 유도체 |
| US11312684B1 (en) | 2021-02-10 | 2022-04-26 | Eleusis Therapeutics Us, Inc. | Pharmaceutically acceptable salts of psilocin and uses thereof |
| WO2022195011A1 (en) * | 2021-03-18 | 2022-09-22 | Cybin Irl Limited | Psilocybin analogs, salts, compositions, and methods of use |
-
2022
- 2022-03-17 CN CN202280022029.2A patent/CN117177959A/zh active Pending
- 2022-09-20 IL IL312175A patent/IL312175A/en unknown
- 2022-09-20 US US18/707,825 patent/US20250213527A1/en active Pending
- 2022-09-20 KR KR1020247017594A patent/KR20240095294A/ko active Pending
- 2022-09-20 EP EP22783493.4A patent/EP4426675A1/en active Pending
- 2022-09-20 AU AU2022381220A patent/AU2022381220B2/en active Active
- 2022-09-20 WO PCT/EP2022/076073 patent/WO2023078604A1/en not_active Ceased
- 2022-09-20 JP JP2024526529A patent/JP2024540282A/ja active Pending
- 2022-09-20 CA CA3236624A patent/CA3236624A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024540282A5 (https=) | ||
| JP2024533291A5 (https=) | ||
| TWI228116B (en) | Monoamine reuptake inhibitors for treatment of CNS disorders | |
| RU2194048C2 (ru) | Производные пиперазина, способ их получения и фармацевтическая композиция | |
| JP6195605B2 (ja) | 薬学的活性剤の製造方法 | |
| ZA200603942B (en) | Derivatives of N-[phenyl(alkylpiperidine-2-yl)methyl]benzamide, preparation method thereof and application of same in therapeutics | |
| US9453027B2 (en) | Deuterium-enriched pyridinonecarboxamides and derivatives | |
| EA023293B1 (ru) | ЛИГАНДЫ НЕЙРОНАЛЬНОГО НИКОТИНОВОГО АЦЕТИЛХОЛИНОВОГО РЕЦЕПТОРА αβ | |
| ZA200603941B (en) | Derivatives of N-[heteroaryl(piperidine-2-yl)methyl]benzamide, preparation method thereof and application of same in therapeutics | |
| JP2009526821A (ja) | 注意欠陥多動性障害治療用の新規な医薬組成物 | |
| CN103214376A (zh) | 取代的4-氨基环己烷衍生物 | |
| JP2011523658A (ja) | アルホルモテロールの合成方法 | |
| TW201002682A (en) | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine | |
| JP2003529586A (ja) | 新規なインドリン−２−オン誘導体、その製造およびそれらを含む医薬組成物 | |
| JP5739415B2 (ja) | （Ｓ）−７−（［１，２，４］トリアゾロ［１，５−ａ］ピリジン−６−イル）−４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロイソキノリンの結晶形態およびその使用 | |
| JP2025510942A5 (https=) | ||
| JP2002508364A (ja) | セロトニン１ａ受容体に対して活性を有するアリールピペラジン | |
| RU2011123890A (ru) | Кристаллическая форма 4-[2-(2-фторфеноксиметил)фенил]пиперидинового соединения | |
| CN101675035A (zh) | 杂环基-取代的-四氢-萘-胺衍生物、其制备及其作为药物的应用 | |
| JP2025502208A5 (https=) | ||
| MXPA01011978A (es) | Nuevas combinaciones farmaceuticas para inhibidores de la nos. | |
| JP2012512145A5 (https=) | ||
| US20230126391A1 (en) | Alpha-methyl-substituted diazabicyclo[4.3.1] decane derivatives for treatment of psychiatric disorders | |
| JPH08509212A (ja) | ４−アリールイソインドール鎮痛薬 | |
| JP2024511597A5 (https=) |